Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by TedOwenson Dec 02, 2013 3:35pm

356 Views

Post# 21961211

RE:RE:RE:RE:Consolodation for Brigus perhaps

St. Andrew has the insider backing to pull the trigger if the goods are there. Black Fox is not part of the story line towards St. Andrew. The Brigus Contact Zone and 147 Zone are part of the Black-Fox trend, Grey-Fox is where there is no gold stream and has no gold stream. Grey-Fox south is the zone which is related to St. Andrew and which has the expansive characteristics in place which will set the stage. 3-6 months will tell the story

Bullboard Posts

High Tide adds two stores to undervalued cannabis retail network